449 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Rank Status Study
21 Recruiting MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Conditions: Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: MART-1 Antigen;   Drug: TLR4 Agonist GLA-SE;   Other: Laboratory Biomarker Analysis
22 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab
23 Recruiting Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Trametinib
24 Recruiting Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Conditions: Malignant Melanoma of Skin Stage III;   Malignant Melanoma of Skin Stage IV
Interventions: Other: arm 1: DC Vaccine + RT;   Other: arm 2: DC Vaccine + IFN-alfa;   Other: arm 3: both arm 1 and 2 + RT;   Biological: arm 4: DC Vaccine
25 Recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
26 Recruiting Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: trametinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
27 Recruiting Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine;   Other: Laboratory Biomarker Analysis
28 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Adult Solid Neoplasm;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Riluzole;   Drug: Sorafenib Tosylate
29 Recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
30 Recruiting Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Conditions: Melanoma Recurrent;   Malignant Melanoma;   Melanoma
Interventions: Biological: Vigil;   Drug: Pembrolizumab
31 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
32 Recruiting Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Conditions: Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma
Interventions: Biological: sargramostim;   Procedure: sentinel lymph node biopsy;   Other: laboratory biomarker analysis;   Other: hypertonic saline
33 Unknown  Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Conditions: Malignant Melanoma of Skin Stage III;   Metastatic Melanoma
Intervention: Drug: Rituxan
34 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
35 Recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
36 Not yet recruiting Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Conditions: Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
37 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Therapeutic Tumor Infiltrating Lymphocytes
38 Recruiting Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Conditions: Metastatic Melanoma;   Melanoma;   BRAF-mutated Metastatic Melanoma;   V600EBRAF-mutated Metastatic Melanoma
Intervention: Drug: Vemurafenib + Cobimetinib, Decitabine
39 Not yet recruiting Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
Conditions: Metastatic Melanoma;   Recurrent Melanoma of the Skin;   Stage IV Skin Melanoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
40 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vorinostat

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years